溶解性 | 25°C: DMSO 67 mg/mL; Water <1 mg/mL; Ethanol 7 mg/mL |
存贮条件 | 储存温度-20°C |
产品介绍 | Pirodavir(R 77975)是一类新型广谱抗小核糖核酸病毒化合物的原型,是人鼻病毒HRV外壳结合抑制剂。 |
生化机理 |
Description: IC50 Value: Pirodavir inhibits 80 percentage of viruses at 0.064 micrograms/ml(EC80)[2]. pirodavir was one of the most promising capsid-binding compounds to show efficacy in human clinical trials for chemoprophylaxis of the common cold. Susceptibility to hydrolysis precluded its use as an oral agent [1]. in vitro: R-77975's predecessor, R 61837, a substituted phenyl-pyridazinamine, was effective in inhibiting 80% of 100 serotypes tested (EC80) at concentrations above 32 micrograms/ml, pirodavir inhibits the same percentage of viruses at 0.064 micrograms/ml. Pirodavir is also effective in inhibiting 16 enteroviruses, with an EC80 of 1.3 micrograms/ml. Pirodavir acts at an early stage of the viral replication cycle (up to 40 min after infection) and reduces the yield of selected rhinoviruses 1,000- to 100,000-fold in a single round of replication [2]. in vivo: Adults with symptoms of < or = 2 days' duration were randomly assigned to intranasal spr |
别名 | R-77975;R77975;R 77975; 吡罗达韦;R-77975;R77975;R 77975;Ethyl 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]benzoate |